+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bacterial Vaginosis Drugs Market by Drug Class (Antibiotics, Antiseptics), Route Of Administration (Oral, Vaginal), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Bacterial Vaginosis Drugs Market by Drug Class (Antibiotics, Antiseptics), Route Of Administration (Oral, Vaginal), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Bacterial Vaginosis Drugs Market by Drug Class (Antibiotics, Antiseptics), Route Of Administration (Oral, Vaginal), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013746
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers navigating the bacterial vaginosis drugs market require clear intelligence to drive strategy amid innovation, evolving patient needs, and a dynamic regulatory environment. This report delivers actionable insight, connecting scientific advances with real-world commercial imperatives to facilitate sound decisions for growth and risk management.

Market Snapshot: Bacterial Vaginosis Drugs Market Progress and Growth

The bacterial vaginosis drugs market grew from USD 921.92 million in 2024 to USD 979.40 million in 2025 and is anticipated to advance at a CAGR of 5.94%, targeting USD 1.30 billion by 2030. This trajectory reflects sustained demand, continuous product development, and persistent challenges in therapeutic effectiveness and patient compliance.

Scope & Segmentation: Comprehensive View Across Therapeutics and Geographies

This report analyzes the bacterial vaginosis therapeutics landscape by covering market sub-segments, application routes, supply chain channels, and global regions, focusing on the following:

  • Drug Classes: Includes antibiotics (clindamycin, metronidazole, tinidazole) and antiseptic formulations, each presenting unique resistance profiles and implications for treatment selection.
  • Route Of Administration: Covers both oral and vaginal options to address variable patient preferences and optimize adherence.
  • Dosage Forms: Assesses cream, gel, suppository, and tablet variants, as innovations continue to impact patient experience and therapeutic outcomes.
  • Distribution Channels: Tracks hospital pharmacy, online pharmacy, and retail pharmacy networks, highlighting distinct procurement and patient access models.
  • End Users: Profiles clinics, home healthcare, and hospitals to gauge different clinical environments and opportunity areas for patient support.
  • Regions: Spans the Americas, Europe, Middle East & Africa, and Asia-Pacific. Sub-regions covered include the United States (across multiple key states), Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland, China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, and Taiwan.
  • Key Companies: In-depth analysis on Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sandoz Inc., Viatris Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, Cipla Limited, Perrigo Company plc, Gedeon Richter Plc, and Glenmark Pharmaceuticals Limited informs competitive positioning.

Key Takeaways: Strategic Insights for Senior Leadership

  • Technological innovation is shaping precise diagnostic tools and digital solutions, improving patient engagement and informing personalized treatments.
  • Integration between laboratory discoveries and commercial offerings remains crucial, with a focus on bridging research and real-world implementation to ensure wide-scale product adoption.
  • Regulatory policies are adapting to foster approval of novel delivery systems and combination therapies, emphasizing both safety and accelerated time-to-market.
  • Regional variation in treatment uptake and regulatory landscape means strategies must be carefully tailored to local reimbursement structures, infrastructure, and public health priorities.
  • Strategic partnerships with diagnostic developers, digital health companies, and regional distributors are driving innovation and reach, especially in response to changing healthcare delivery models.
  • Market leaders are leveraging intellectual property strategies and lifecycle management to maintain differentiation and secure long-term presence amid patent expirations.

Tariff Impact: Navigating Shifts in Trade and Supply Chain Structure

United States tariff policies in 2025 have added complexity to the global supply chain for bacterial vaginosis therapeutics. Manufacturers are reassessing sourcing and cost structures, with procurement teams considering alternative suppliers to balance affordability and quality. Distributors and wholesalers are streamlining logistics and renegotiating contracts, while healthcare providers may move toward generics to manage incremental cost increases. Developing agile supply chain frameworks and tariff risk protocols is now critical.

Methodology & Data Sources: Ensuring Analytical Integrity

The report employs a robust approach, integrating primary interviews with clinicians, industry executives, and supply chain experts alongside secondary research from peer-reviewed journals, regulatory filings, and public health data. Layered cross-verification and statistical analysis produce unbiased, theme-based insights that accurately reflect the current market and competitive environment.

Why This Report Matters: Actionable Value for Decision Makers

  • Delivers a complete picture of product, regional, and competitor dynamics to inform investment and operational strategy.
  • Provides evidence-based recommendations specifically aligned to senior leadership’s need for risk mitigation, opportunity identification, and market entry optimization.
  • Enables proactive navigation of evolving regulatory, supply chain, and tariff issues with data-backed intelligence.

Conclusion

Senior leaders equipped with a holistic understanding of the bacterial vaginosis drugs market can anticipate industry shifts, adjust strategies confidently, and capitalize on growth prospects while meeting clinical and commercial objectives.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of targeted probiotic vaginal suppositories to reduce bacterial vaginosis recurrence
5.2. Escalating R&D investment in non-antibiotic biofilm disruptors for BV treatment modalities
5.3. Regulatory fast track approvals accelerating clinical availability of novel BV therapies
5.4. Strategic partnerships between biotech startups and pharma giants driving BV pipeline expansion
5.5. Advancements in rapid diagnostic tests enabling personalized BV drug regimens at point of care
5.6. Rising prevalence of antibiotic-resistant vaginal microbiota fueling demand for alternative BV therapies
5.7. Emergence of long acting vaginal inserts combining antimicrobial and anti inflammatory agents for BV prevention
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bacterial Vaginosis Drugs Market, by Drug Class
8.1. Introduction
8.2. Antibiotics
8.2.1. Clindamycin
8.2.2. Metronidazole
8.2.3. Tinidazole
8.3. Antiseptics
9. Bacterial Vaginosis Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Vaginal
10. Bacterial Vaginosis Drugs Market, by Dosage Form
10.1. Introduction
10.2. Cream
10.3. Gel
10.4. Suppository
10.5. Tablets
11. Bacterial Vaginosis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Bacterial Vaginosis Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Healthcare
12.4. Hospitals
13. Americas Bacterial Vaginosis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Bacterial Vaginosis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Bacterial Vaginosis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Ltd.
16.3.2. Pfizer Inc.
16.3.3. Sandoz Inc.
16.3.4. Viatris Inc.
16.3.5. Dr. Reddy's Laboratories Ltd
16.3.6. Lupin Limited
16.3.7. Cipla Limited
16.3.8. Perrigo Company plc
16.3.9. Gedeon Richter Plc
16.3.10. Glenmark Pharmaceuticals Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BACTERIAL VAGINOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BACTERIAL VAGINOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BACTERIAL VAGINOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BACTERIAL VAGINOSIS DRUGS MARKET: RESEARCHAI
FIGURE 26. BACTERIAL VAGINOSIS DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. BACTERIAL VAGINOSIS DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. BACTERIAL VAGINOSIS DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BACTERIAL VAGINOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 83. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 84. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 85. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 86. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 87. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 98. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 99. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 158. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 159. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 160. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 161. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 164. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 165. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 172. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 173. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 176. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 177. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. RUSSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 194. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 195. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 196. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 197. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 200. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 201. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 206. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 207. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 208. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 209. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 212. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 213. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. SPAIN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SOUTH AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 256. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 257. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 260. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 261. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 278. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 279. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 280. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 281. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 284. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 285. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 290. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 291. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 292. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 293. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 296. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 297. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 302. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. SWEDEN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 314. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA B

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Bacterial Vaginosis Drugs market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Sandoz Inc.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd
  • Lupin Limited
  • Cipla Limited
  • Perrigo Company plc
  • Gedeon Richter Plc
  • Glenmark Pharmaceuticals Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 979.4 Million
Forecasted Market Value ( USD ) by 2030 $ 1300 Million
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hospital Infection Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antiseptics), Route Of Administration (Inhalation, Oral, Parenteral), End User, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Hospital Infection Therapeutics Market by Drug Class (Antibiotics, Antifungals, Antiseptics), Route Of Administration (Inhalation, Oral, Parenteral), End User, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Bacterial Vaginosis Drug Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Dosage Form, Distribution Channel, and Geography - Product Image

Bacterial Vaginosis Drug Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Dosage Form, Distribution Channel, and Geography

  • Report
  • 184 Pages
  • Global
From
Bacterial Vaginosis - Pipeline Insight, 2025 - Product Image

Bacterial Vaginosis - Pipeline Insight, 2025

  • Clinical Trials
  • 40 Pages
  • Global
From
Pregnancy and Anti-Infective Agents - Product Image

Pregnancy and Anti-Infective Agents

  • Book
From
Cephalexin Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Cephalexin Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From

About the Bacterial Vaginosis Drug Market

Bacterial Vaginosis (BV) is a common vaginal infection caused by an imbalance of bacteria in the vagina. BV is typically treated with antibiotics, such as metronidazole, clindamycin, and tinidazole. These antibiotics are part of the Infectious Diseases Drugs market, which includes drugs used to treat a variety of bacterial, viral, and fungal infections. The Bacterial Vaginosis Drug market is a subset of the Infectious Diseases Drugs market, and is composed of antibiotics used to treat BV. These drugs are typically prescribed in the form of oral tablets, topical creams, and vaginal gels. Some companies in the Bacterial Vaginosis Drug market include Pfizer, Merck, GlaxoSmithKline, and Bayer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.